Loading stock data…
MRNA
$45.37-0.57 (-1.24%)
Market ClosedLast close May 1
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moderna, Inc. in the Healthcare sector is trading at $45.37. The stock is currently 24% below its 52-week high of $59.55, remaining 27.1% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why MRNA maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$45.37
Potential Upside
5%
Whystock Fair Value$47.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Hold
Mean target$41.42-8.7%
Range$21.00 – $69.00
Fundamentals
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pand...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.56%
Volume
Today's trading volume
10.21M
Recent News
Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake
We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 7th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) has been a consistent feature in the 13F portfolio of Greenlight Capital since the first quarter of 2024. Back then, this position comprised 4.1 million shares. By the […]
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026
Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), making it the world’s first mRNA combination vaccine for influenza and COVID-19 to receive such approval. Authorized for adults aged 50 and older, the single-dose vaccine is […]
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect
MRNA heads into Q1 earnings with expected sales growth, new vaccine momentum and focus on pipeline updates amid tough RSV competition.
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal?
Investors may be wondering whether Moderna's current share price reflects its true value, or if the market is still trying to figure the company out. The stock closed at US$48.69, with a 10.8% decline over the last 7 days and a 1.8% decline over 30 days, but gains of 57.8% year to date and 77.3% over the last year. The 3 year and 5 year returns stand at 63.5% and 73.8% declines, respectively. Recent headlines around Moderna continue to frame it as a key name in the biotech space, with...
Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 8th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roivant’s subsidiaries, Genevant and Arbutus, reached a $2.25 billion global settlement with Moderna over a COVID-19 vaccine patent. This […]